Slide 1: Third quarter 2022 results
Third quarter 2022 results Audiocast presentation 10 November 2022 Q3
Slide 2: Forward looking statements
2 Forward looking statements This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance. Camurus is providing the following cautionary statement. Such forward-lo
Slide 3: Agenda
3 Agenda • Third quarter highlights Company participants • Financial performance Fredrik Tiberg, PhD • Commercial development President & CEO, CSO • R&D pipeline progress Jon Garay Alonso Chief Financial Officer • Q&A Richard Jameson Chief Commercial Officer
Slide 4: Camurus' third quarter highlights
4 Camurus’ third quarter highlights Best financial quarter to date Commercial execution Pipeline and corporate development Third consecutive quarter of Strengthened leadership in opioid Registration processes for indication positive operating result dependence treatment expansion to chronic pa
Slide 5: Financial performance
camurus. Financial performance
Slide 6: Q3 growth contributing to profitability
6 Q3 growth contributing to profitability Revenue Operating Result Revenue growth MSEK +57% vs Q3 2021 MSEK 700 688 100 Operating result 600 +65% 50 41 53 +48 MSEK vs Q3 2021 500 418 +48 MSEK Cash position 400 0 -6 +146 MSEK SEK 520 million Q3 -23 300 241 -50 +22% vs Q3 2021 230 200 +57% 154 100 -10
Slide 7: Reported Quarter profit and loss and FY 2022 outlook
7 Reported Quarter profit and loss and FY 2022 outlook CER CER MSEK Jul – Sep Change Change Jan – Sep Change Change 2022 vs. 2021 vs. 2021 2022 vs. 2021 vs. 2021 Total revenues 241 +57% +45% 688 +65% +55% Improved FY 2022 outlook2 Gross margin 217 +364bps +285bps 613 +275bps +206bps Total revenue1 S
Slide 8: Strong cash generation – No debt
8 Strong cash generation – No debt •Continued improvement in cash flow from operations MSEK Capital allocation priorities • Reinvest in our business: ‒ Buvidal market penetration & geographical expansion ‒ CAM2029 development to market • Synergistic inorganic growth opportunities enhancing company v
Slide 9: Commercial update
camurus. Commercial update
Slide 10: Continued Buvidal market penetration
10 Continued Buvidal market penetration •Robust sales growth •Quarterly product sales ‒ SEK 241 million sales (+58% vs. Q3 2021, +7% vs. Q2 2022) MSEK ‒ Significant growth across markets 250 241 225 • Growth slowed down during the European vacations with fewer new patients initiating treatment 202 2
Slide 11: Growing scientific evidence base
11 Growing scientific evidence base Selected scientific conference participation in 2022 and 2023 Key publications Q3 20221-3 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3/Q4 2023 Global IASP ASAM CPDD ISAM 16-18 Feb 13-16 Apr 17-21 Jun 2-4 Nov Luxor, EG Washington, US Denver, US Marrakesh, MA European Nordic
Slide 12: Market expansion to the US
12 Market expansion to the US •Brixadi1 NDA resubmission status •Ongoing US investigator sponsored studies FDA inspection of Braeburn’s third party manufacturer STUDY EST. PATIENTS Resubmission of Brixadi new drug applications (NDA) for MOMs3 200 opioid use disorder (OUD) Medication Treatment fo
Slide 13: R&D pipeline developments
13 R&D pipeline developments
Slide 14: Broad and diversified pipeline for sustainable growth
14 Broad and diversified pipeline for sustainable growth Phase 1 Phase 2 Phase 3 Registration CAM2043 CAM2029 CAM2029 Brixadi™ Pulmonary arterial Polycystic liver disease Acromegaly Opioid use disorder (US)1 hypertension CAM2047 CAM2032 CAM2029 Buvidal® Chemotherapy-induced Prostate cancer Gastroent
Slide 15: CAM2029 update
15 CAM2029 update •Octreotide SC depot under assessment in three, serious rare disease indications • Acromegaly • Gastroenteropancreatic neuroendocrine tumors (GEP-NET) • Polycystic liver disease (PLD) •Designed for enhanced efficacy and patient convenience
Slide 16: CAM2029 in acromegaly: AcroInnova update
16 CAM2029 in acromegaly: AcroInnova update •Pivotal randomized, placebo-controlled Phase 3 trial ‒ Rigorous, 24-week, randomized, double-blind, placebo-controlled trial ‒ Primary endpoint biochemical response (IGF-1≤1xULN) ‒ Filling regulatory requirement for efficacy Two Phase 3 trials ongoing •
Slide 17: CAM2029 in NET: SORENTO update
17 CAM2029 in NET: SORENTO update •Multinational, randomized, active-controlled Phase 3 trial ‒ Primary endpoint is superiority in progression free survival, PFS, versus octreotide LAR and lanreotide ATG ‒ Assessed after 194 progression events ‒ Multiple patient reported outcomes included in study
Slide 18: November 10th is the World NET Cancer Day
18 November 10th is the World NET Cancer Day
Slide 19: CAM2029 in PLD: POSITANO update
19 CAM2029 in PLD: POSITANO update •Significant unmet need with no approved treatment ‒ PLD is a rare, genetic and chronic disorder ‒ Progressive growth of cysts in the liver, can cause severe symptoms ‒ Estimated ~30,000 patients with symptomatic PLD1 ‒ No approved medical treatment – increased sci
Slide 20: Other rare disease opportunities
20 Other rare disease opportunities Setmelanotide SC depot, CAM4072 •Treprostinil SC depot, CAM2043 ‒ Driven by license partner Rhythm ‒ Targeting high medical need in treating ‒ Positive PK and PD results in Phase 2a MAD study Raynaud’s Phenomenon and PAH ‒ Phase 3 trial ongoing in switch patients
Slide 21: Third quarter take-aways
21 Third quarter take-aways Growing revenues and profitability Buvidal market expansion in EU and MENA Late-state pipeline progressing according to plan Improved result guidance confirming full year profitability
Slide 22: Q&A
camurus. O&A
Slide 23: Experienced and committed management team
23 Experienced and committed management team Fredrik Tiberg, PhD Education: M.Sc. in Chem. Eng., Lund Institute of Technology, Jon Garay Alonso Education: Bachelor in Business Administration by President & CEO, CSO PhD and Assoc. Prof. Physical Chemistry, Lund University. Chief Financial Officer Uni
Slide 24: Shareholders and analyst coverage
24 Shareholders and analyst coverage Shareholders as of 31 October 2022 Number of shares % of capital % of votes Sandberg Development AB 21,875,692 39.5 39.5 Fjärde AP-fonden 3,502,450 6.3 6.3 Avanza Pension 2,401,362 4.3 4.3 Analysts Didner & Gerge Fonder 2,332,561 4.2 4.2 Fredrik Tiberg, CEO 1,680